Simple Summary The effectiveness and safety of the anti-cancer agent doxorubicin
(anthracycline group medicine) depend on the metabolism and retention of the drug in the …

Introduction: A large number of genetic polymorphisms have been reported in the genes that
mediate the metabolism, transport and pharmacological activity of doxorubicin. The clinical …

Increased understanding of the molecular mechanisms of tumor heterogeneity combined
with rapid advances in the field of pharmacogenetics and pharmacogenomics have fuelled …

Background: Doxorubicin and cyclophosphamide (AC) therapy is an effective treatment for
early-stage breast cancer. Doxorubicin is a substrate for ABCB1 and SLC22A16 …

Abstract Learning Objectives After completing this course, the reader will be able to: List
currently identified candidate genes involved in phase I metabolism that are potential …

Large differences are observed in chemotherapy response between breast cancer patients,
with a substantial part of this variability being explained by genetic factors. Polymorphisms in …

The goal of this study is to give a brief background on the literature supporting the
PharmGKB pathway about doxorubicin action, and provides a summary of this active area of …

In the treatment of cancer, a narrow therapeutic window generally exists between toxicity
and suboptimal therapy. In addition, interindividual variation in drug metabolism seriously …

Pharmacogenomics is based on the understanding of the individual differences in drug use,
the response to drug therapy (efficacy and toxicity), and the mechanisms underlying variable …

The inter-individual differences in cancer susceptibility are somehow correlated with the
genetic differences that are caused by the polymorphisms. These genetic variations in drug …